On August 1, the U.S. Food and Drug Administration (FDA) released a new Guidance for Industry, “Antibacterial Therapies for Patients with an Unmet Medical Need for the Treatment of Serious Bacterial Diseases.” The guidance is not binding or legal, but is a recommendation for those working to develop or support the development of new pathogen-focused antibacterial drugs and presents opportunities to streamline development to have medications available for those with unmet medical needs. This and similar guidance, programs, and incentives are part of a broader international approach to facilitate and encourage the development of new options in the face of the growing threat of antimicrobial resistance. Click here to access the full report and learn more.
More NACCHO Blogs
The Essential Elements of Local Public Health
The Essential Elements of Local Public Health provides updates and information from NACCHO’s Environmental Health and Infectious Disease portfolios.
The Preparedness Brief provides updates and information from NACCHO’s public health preparedness portfolio.